Nanocopoeia
Nanocopoeia is a privately held specialty research company that uses its proprietary ElectronanoSpray (ENS) atomization technology to solve drug insolubility and bioavailability challenges, partnering with pharmaceutical companies on co-development and out-licensing of 505(b)(2) oral-solid drug opportunities.
- Company typePrivate
- Founded2001
- HeadquartersMinneapolis, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Nanocopoeia does
Nanocopoeia, LLC is a privately held specialty research company founded in 2001 in the Twin Cities, Minnesota area, through a technology license with the University of Minnesota. Originally operating as a business-to-business technology services provider focused on medical devices and advanced nano-scale coatings, the company reorganized around 2021 to pivot toward generating macro-particles for oral-solid drug development. It targets pharmaceutical partners facing high-value, high-barrier insolubility, bioavailability, and related drug-product challenges, with particular emphasis on 505(b)(2) development opportunities.
The company's core product is its proprietary ElectronanoSpray (ENS) atomization platform, developed from the Taylor Cone hydrodynamic principle operating in Cone-jet mode. The high-voltage unipolar atomization process produces homogeneous, macro-scale drug-formulation particles with high surface area and uniformity, using common pharmaceutical-grade excipients and solvents that are removed to residual levels well below ICH requirements. The ENS platform is positioned as a tool to overcome challenging insolubility issues, increase bioavailability, reduce defects, and improve patient safety, convenience, compliance, and drug effectiveness.
Nanocopoeia monetizes through a B2B technology services model and co-development/out-licensing arrangements with pharmaceutical partners. Revenue streams are described as professional services for nano-scale coating and formulation work, paired with licensing and royalty arrangements tied to co-developed drug products. The company has a small team of 11-50 employees, backed by what it describes as substantial but undisclosed investor capital, and operates from its headquarters at 639 Campus Drive, New Brighton, MN.
Nanocopoeia firmographics
Firmographics- Name
- Nanocopoeia
- Legal name
- Nanocopoeia, LLC
- Website
- https://nanocopoeia.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nanocopoeia is a privately held specialty research company that uses its proprietary ElectronanoSpray (ENS) atomization technology to solve drug insolubility and bioavailability challenges, partnering with pharmaceutical companies on co-development and out-licensing of 505(b)(2) oral-solid drug opportunities.
- Ownership category
- akta.pro rank
Nanocopoeia industry classification
Industry- Product category
- Pharmaceutical Drug Formulation Services
- NAICS
- Research and Development in Nanotechnology (541713), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)
- akta.pro secondary industries
- Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Nanocopoeia is headquartered
LocationHeadquarters
- HQ city
- Minneapolis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nanocopoeia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Technology Services: Business-to-business technology services model providing nano-scale coating processes and drug formulation capabilities to pharmaceutical partners.
- Co-development and Licensing: Co-development partnerships and out-licensing of drug formulations for oral-solid drug development, particularly 505(b)(2) opportunities.
Go-to-market motion1 record
Distribution channels1 record
Nanocopoeia product offering
Product offeringCore offering
Nanocopoeia provides pharmaceutical drug formulation services using its proprietary ElectronanoSpray (ENS) atomization technology, which creates homogeneous, macro-scale drug particles that overcome challenging insolubility issues and improve bioavailability performance. The company operates a B2B technology services and co-development model, partnering with pharmaceutical companies on oral-solid drug development, including 505(b)(2) opportunities, and out-licensing its formulations.
Product overview
Nanocopoeia is a specialty research company offering a unified technology platform centered on its proprietary ElectronanoSpray (ENS) atomization technology. The company operates a business-to-business technology services model, providing pharmaceutical companies with access to its ENS platform for drug formulation development. ENS enables the creation of macro-scale drug particles that overcome insolubility challenges and improve bioavailability performance, supporting 505(b)(2) drug development opportunities.
Differentiator
Problem solved
Functional benefit
Products and services
- ElectronanoSpray (ENS) Technology Platform Proprietary atomization technology based on the Taylor Cone hydrodynamic principle operating in Cone-jet mode. Produces homogeneous, macro-scale drug formulation particles with high surface area and uniformity, addressing insolubility and bioavailability challenges in pharmaceutical development for 505(b)(2) opportunities.
- Pharmaceutical Co-development and Out-licensing Services B2B engagement offering pharmaceutical partners co-development and out-licensing arrangements using the ENS platform, focused on building long-term value on oral-solid drug products targeting 505(b)(2) development pathways.
Quantifiable outcome
- Residual solvents (RS) proving to be well below ICH requirements
Companies that use Nanocopoeia
Customer profileSegments1 record
Ideal customer profiles1 record
Nanocopoeia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Nanocopoeia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of MinnesotacoreTechnology licensing partnership established in 2001 through which Nanocopoeia was founded. Initial technology focused on medical devices and advanced nano-scale coating processes.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
Nanocopoeia competitors and assessment
Company assessmentDirect peers
- Bend Research (part of Lonza): A bioavailability and solubility-focused formulation CRO/CDMO, now part of Lonza, specializing in spray-dried dispersions and particle engineering for poorly soluble drugs — directly comparable to Nanocopoeia's ENS platform and 505(b)(2) partner model.
- Hovione: CDMO with strong particle engineering, spray drying, and bioavailability-enhancement capabilities, serving pharmaceutical partners with similar formulation services and tech-platform partnering models.
- Solvias: CRO/CDMO with deep solid-state chemistry, preformulation, and particle engineering expertise, serving pharma clients on solubility and bioavailability challenges — closely comparable to Nanocopoeia's technical focus.
- Crystal Pharmatech: Specialty CRO focused on solid-form selection, crystallization, and preformulation services for poorly soluble drugs — closely aligned with Nanocopoeia's solubility/bioavailability value proposition.
Broad incumbents
- Catalent: Large global CDMO offering broad formulation, bioavailability, and drug product development services including OptiForm® and similar solubility-enhancement platforms — overlaps Nanocopoeia's scope at much greater scale.
- Patheon (Thermo Fisher Scientific): Major global CDMO providing drug substance and drug product development including formulation services for poorly soluble compounds — broad incumbent with overlapping capabilities.
- Lonza: Global CDMO leader offering bioavailability and formulation services including the Bend Research platform — a broad incumbent whose overlapping capabilities directly compete with Nanocopoeia.
Emerging players
- Vectura Group (Philip Morris International): Specialty formulation and drug delivery company with proprietary particle engineering technologies for inhaled and oral formulations — comparable in platform-based approach to addressing drug delivery challenges.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Nanocopoeia social profiles
Digital presenceNanocopoeia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nanocopoeia leadership team
Management profileNumber of profiles
Profiles7 records
Nanocopoeia funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nanocopoeia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nanocopoeia
What does Nanocopoeia do?
Nanocopoeia provides pharmaceutical drug formulation services using its proprietary ElectronanoSpray (ENS) atomization technology, which creates homogeneous, macro-scale drug particles that overcome challenging insolubility issues and improve bioavailability performance. The company operates a B2B technology services and co-development model, partnering with pharmaceutical companies on oral-solid drug development, including 505(b)(2) opportunities, and out-licensing its formulations.
Is Nanocopoeia a public or private company?
Nanocopoeia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nanocopoeia founded?
Nanocopoeia was founded in 2001. It employs 11 to 50 people.
Where is Nanocopoeia based?
Nanocopoeia is headquartered in Minneapolis, United States, in the North America region.
How does Nanocopoeia make money?
Two revenue lines are on record. Technology Services are the primary driver. The others are co-development and Licensing.
Who are Nanocopoeia's main competitors?
Direct peers on record are Bend Research (part of Lonza), Hovione, Solvias and Crystal Pharmatech. Broad incumbents are Catalent, Patheon (Thermo Fisher Scientific) and Lonza. Vectura Group (Philip Morris International) is listed as an emerging player.
Does Nanocopoeia have an API?
No public API is recorded for Nanocopoeia.
What industry is Nanocopoeia in?
Nanocopoeia's product category is Pharmaceutical Drug Formulation Services. Its primary akta.pro industry code is HLAGAHAJ, Crystallization, Particle Engineering & Micronization Services, with a secondary code of HLAGAHAI, Solid-State Chemistry & Preformulation (Polymorph/Crystallization). Its NAICS code is 541713 and its SIC code is 8731.